A Comprehensive Guide to ICD-10-CM Code for Elevated Bilirubin

A simple blood test reveals an elevated bilirubin level. In the electronic health record (EHR), it flashes as an abnormal value, a biochemical hint wrapped in a clinical mystery. This golden-yellow pigment, a byproduct of heme breakdown, is more than just a lab figure; it is a storyteller. Its elevation—hyperbilirubinemia—can whisper of a benign, physiological process or scream of a life-threatening hepatic or hematological crisis. For the medical coder, translating this story into the precise alphanumeric language of ICD-10-CM is a task of paramount importance. It is the bridge between clinical observation and actionable data, influencing patient care trajectories, reimbursement accuracy, and epidemiological research. This article delves deep into the intricate world of coding for elevated bilirubin, moving far beyond the basic code to explore the nuance, specificity, and clinical understanding required to master this essential aspect of medical documentation.

2. The Physiology of Bilirubin: A Lifecycle in Brief

To code accurately, one must understand the pathophysiology. Bilirubin originates from the breakdown of red blood cells (RBCs) in the spleen. This “unconjugated” or “indirect” bilirubin is bound to albumin and transported to the liver. Here, via the enzyme UDP-glucuronosyltransferase, it is conjugated with glucuronic acid, making it water-soluble. This “conjugated” or “direct” bilirubin is then excreted into bile, stored in the gallbladder, and released into the intestines. Gut bacteria convert it to urobilinogen, which is either excreted in feces (giving stool its brown color) or reabsorbed and excreted by the kidneys.

Hyperbilirubinemia, and thus jaundice (the visible yellowing of skin and sclera), occurs when this delicate balance is disrupted:

• Pre-hepatic: Excessive RBC breakdown (hemolysis) overwhelms the liver’s conjugation capacity (e.g., sickle cell crisis, hereditary spherocytosis). Predominantly Unconjugated.

• Hepatic: Liver cell (hepatocyte) dysfunction impairs uptake, conjugation, or excretion (e.g., hepatitis, cirrhosis, Gilbert’s syndrome). Can be Mixed or Unconjugated.

• Post-hepatic/Obstructive: Blockage of bile flow prevents excretion (e.g., choledocholithiasis, pancreatic head carcinoma, biliary stricture). Predominantly Conjugated.

The differentiation between conjugated and unconjugated bilirubin, determined by a fractionated bilirubin test, is the first critical clue for the clinician and the coder.

3. Why Code Accurately? The Implications of Hyperbilirubinemia Coding

Accurate ICD-10-CM coding for elevated bilirubin is not a clerical afterthought. It is a foundational activity with wide-ranging impacts:

• Patient Care: Specific codes help track disease prevalence, complications, and outcomes. They can trigger clinical decision support tools and care pathways.

• Reimbursement: Codes justify the medical necessity of diagnostic tests (like MRCP or liver biopsy), procedures (like ERCP), and hospital admissions. Incorrect coding can lead to claim denials or audits.

• Research & Public Health: Aggregated coded data is used for epidemiological studies, tracking disease outbreaks (e.g., hepatitis A), and allocating public health resources.

• Healthcare Analytics: Systems use coded data to analyze provider performance, hospital resource utilization, and population health trends.

Using a nonspecific code like R17.9 when a more precise code is available is a missed opportunity on all these fronts.

4. The ICD-10-CM Code for Elevated Bilirubin: The Core Codes

The ICD-10-CM index directs us from “Hyperbilirubinemia” to a range of codes, primarily located in two chapters:

• Chapter 18: Symptoms, Signs, and Abnormal Clinical and Laboratory Findings, Not Elsewhere Classified (R00-R99)

• Chapter 16: Certain Conditions Originating in the Perinatal Period (P00-P96)

The most direct entry is R17 – Unspecified hyperbilirubinemia. However, as we will see, “unspecified” is often a last resort.

5. Navigating the Neonate: A World of Separate Codes (P58, P59 Series)

Hyperbilirubinemia in newborns is so common and its etiology so distinct that ICD-10-CM dedicates an entire block to it. Codes from the P58 and P59 series take precedence over R17 for conditions originating in the perinatal period.

• P58.- Neonatal jaundice due to other excessive hemolysis: This code series is used for jaundice specifically caused by hemolysis.

  • P58.0 Neonatal jaundice due to bruising: From birth trauma like cephalohematoma.

  • P58.1 Neonatal jaundice due to bleeding: From internal hemorrhage.

  • P58.2 Neonatal jaundice due to infection: e.g., sepsis.

  • P58.3 Neonatal jaundice due to polycythemia:

  • P58.4 Neonatal jaundice due to drugs or toxins transmitted from mother: Requires an additional code from T36-T50 for the specific drug.

  • P58.5 Neonatal jaundice due to swallowed maternal blood: (e.g., from cracked nipples).

  • P58.8 Neonatal jaundice due to other specified excessive hemolysis: (e.g., specific inherited hemolytic anemias like G6PD deficiency, if diagnosed).

  • P58.9 Neonatal jaundice due to excessive hemolysis, unspecified.

• P59.- Neonatal jaundice from other and unspecified causes: This is for non-hemolytic or physiological jaundice.

  • P59.0 Neonatal jaundice associated with preterm delivery: “Preemie jaundice.”

  • P59.1 Inspissated bile syndrome: Thickened bile causing obstruction.

  • P59.2 Neonatal jaundice from other and unspecified hepatocellular damage:

  • P59.3 Neonatal jaundice from breast milk inhibitors: “Breast milk jaundice.”

  • P59.8 Neonatal jaundice from other specified causes:

  • P59.9 Neonatal jaundice, unspecified: Often used for “physiological jaundice” when no specific cause is identified.

 Guide to Neonatal Hyperbilirubinemia Coding

6. The Adult Landscape: R17 and Its Essential Fourth Digit

For adults (and children outside the perinatal period), the journey typically starts in the R17 category. The fourth digit is mandatory and is based on the presence or absence of jaundice.

• R17.0 Hyperbilirubinemia, unspecified with jaundice: This is used when the patient has clinical jaundice (yellowing of skin/sclera) documented, but the type of hyperbilirubinemia (conjugated vs. unconjugated) is not specified, and no underlying cause is identified as the reason for the encounter.

• R17.9 Hyperbilirubinemia, unspecified without jaundice: This is used for laboratory-only findings—elevated bilirubin on blood work without visible jaundice. Again, the type and cause are unspecified.

Crucially, both R17.0 and R17.9 are “unspecified” and should be used sparingly. They are appropriate only when hyperbilirubinemia is a incidental finding that is not further investigated during that encounter, or when the cause is truly unknown after initial workup. The official coding guidelines state: “Signs and symptoms that are associated routinely with a disease process should not be assigned as additional codes.” This leads us to the most critical concept in coding elevated bilirubin.

7. The Critical Importance of Etiology: Moving Beyond the Sign

Elevated bilirubin is almost always a sign of an underlying disease. ICD-10-CM guidelines instruct us to code the established underlying etiology instead of the sign, when known. The code for the underlying condition is sequenced first, and a code like R17 may not be necessary at all if the jaundice/hyperbilirubinemia is an integral part of that condition’s clinical picture.

8. Common Underlying Conditions and Their Corresponding Codes

Here is how coding shifts from the sign to the cause:

• Alcoholic Liver Disease: Code first K70.- (e.g., K70.10 Alcoholic hepatitis). Jaundice is a classic symptom.

• Viral Hepatitis: Code first B15-B19 (e.g., B18.2 Chronic viral hepatitis C). Hyperbilirubinemia is a defining feature.

• Choledocholithiasis (Bile Duct Stones): Code first K80.3-K80.5. The obstruction causes conjugated hyperbilirubinemia.

• Malignant Neoplasm of Pancreas Head: Code first C25.0. Jaundice is a frequent presenting sign.

• Autoimmune Hepatitis: Code first K75.4.

• Cirrhosis: Code first K74.-. Jaundice indicates decompensation.

• Hemolytic Anemias (e.g., Sickle Cell, Spherocytosis): Code first D55-D59. The hyperbilirubinemia is unconjugated.

• Gilbert’s Syndrome: Code E80.4. This is the definitive diagnosis for mild, chronic, unconjugated hyperbilirubinemia.

• Adverse Effect of a Drug: Code first the specific T36-T50 code with 5th/6th character for adverse effect, followed by the liver manifestation (e.g., K71.2 Toxic liver disease with cholestasis).

9. The Art of Sequencing: Which Code Comes First?

The sequencing order is dictated by the reason for the encounter as documented in the record.

• Scenario A (Underlying Cause Managed): A patient with known cirrhosis (K74.60) is admitted for worsening jaundice and hepatic encephalopathy. The reason for admission is the decompensated cirrhosis. Sequence K74.60 first. You may add R17.0 if the jaundice is being specifically monitored or treated, but often it’s integral.

• Scenario B (Sign Investigated): A patient presents to their PCP with new-onset jaundice and fatigue. After workup, they are diagnosed with acute hepatitis A. The encounter was for the investigation of a sign. Sequence B15.9 (Hepatitis A) first. R17.0 may be assigned as an additional code if the jaundice required separate evaluation, but it’s often redundant.

• Scenario C (Incidental Finding): A patient is seen for follow-up of hypertension. Routine labs show an asymptomatic, mild elevation of unconjugated bilirubin. No workup is initiated. The hyperbilirubinemia is incidental. Code for the hypertension (I10) and R17.9 as a secondary finding.

10. Clinical Documentation Improvement (CDI) for Precise Coding

Clear documentation is the coder’s lifeline. CDI specialists and coders can advocate for specificity by encouraging providers to document:

1. The Type: Is it “conjugated (direct),” “unconjugated (indirect),” or “mixed” hyperbilirubinemia?

2. The Presence of Jaundice: Explicitly note “icterus noted” or “scleral icterus present.”

3. The Suspected or Confirmed Etiology: “Jaundice secondary to pancreatic mass,” “Elevated bilirubin due to hemolysis from sepsis,” etc.

4. In Neonates: The specific cause (physiological, breastfeeding-related, ABO incompatibility, etc.).

11. Case Studies: Applying the Knowledge

Case 1: A 45-year-old male presents to the ED with severe RUQ pain, fever, and yellow eyes. Ultrasound shows stones in the common bile duct. He is admitted for ERCP.

• Principal Diagnosis: K80.42 (Calculus of bile duct with acute cholangitis with obstruction).

• Additional Code: R17.0 could be added, but the jaundice is an inherent part of the cholangitis/obstruction. Likely not needed.

Case 2: A 3-day-old newborn is noted to have jaundice. Bilirubin is elevated, mostly unconjugated. Mother is O+, baby is A+. Diagnosis: ABO incompatibility.

• Principal Diagnosis: P55.1 (Hemolytic disease due to ABO isoimmunization). Not R17 and not P58.8.

Case 3: A patient is seen in oncology follow-up for pancreatic cancer. The note states: “Patient here for follow-up of C25.0, status post Whipple. Currently has persistent jaundice, managing with stents.”

• Principal Diagnosis: C25.0 (Malignant neoplasm of head of pancreas). The jaundice is a direct consequence.

12. Conclusion

Accurately coding elevated bilirubin requires moving from a simple sign to a detailed clinical narrative. It demands an understanding of physiology, a mastery of ICD-10-CM chapter-specific guidelines, and a relentless pursuit of specificity. By prioritizing underlying etiology, correctly applying neonatal codes, and using unspecified codes (R17) judiciously, coders transform a lab value into a powerful data point that drives quality care, ensures financial integrity, and fuels the insights that advance modern medicine.

13. Frequently Asked Questions (FAQs)

Q1: Can I use both an underlying cause code and R17?
A: Yes, but only if the hyperbilirubinemia or jaundice itself is being separately evaluated or treated, beyond the routine management of the underlying condition. In most cases, it is redundant. Follow the coding guidelines on associated signs/symptoms.

Q2: What is the difference between Gilbert’s syndrome (E80.4) and using R17.9?
A: E80.4 is a diagnosis—a specific, benign genetic condition causing mild unconjugated hyperbilirubinemia. R17.9 is a sign of an unspecified problem. If Gilbert’s is confirmed, code E80.4, not R17.9.

Q3: How long is a newborn considered a “neonate” for coding purposes?
A: The perinatal period (Chapter 16) is defined as conditions originating before birth through the first 28 days after birth. Use P-codes for hyperbilirubinemia originating during this time, even if the condition is diagnosed or persists beyond 28 days.

Q4: What if the bilirubin is elevated, but the note only says “abnormal LFTs”?
A: If “hyperbilirubinemia” or “jaundice” is not documented, you cannot code it. You could use R79.89 (Other specified abnormal findings of blood chemistry) for the abnormal bilirubin level, but this is less specific. Query the provider for clarity.

Q5: A patient has jaundice from metastatic liver disease. What do I code?
A: Code first the primary malignancy (e.g., C18.9 Colon cancer), then C78.7 (Secondary malignant neoplasm of liver). Jaundice is a symptom of the liver mets; an R17.0 code is typically not needed.

14. Additional Resources

• Centers for Medicare & Medicaid Services (CMS): Official ICD-10-CM Guidelines, Code Tables, and Index: https://www.cms.gov/medicare/coding-billing/icd-10-codes

• American Hospital Association (AHA) Coding Clinic: The authoritative source for official coding advice and guidance.

• American Health Information Management Association (AHIMA): Provides educational resources and best practices for clinical documentation and coding.

• National Library of Medicine – MedlinePlus: Hyperbilirubinemia Patient Information: https://medlineplus.gov/ency/article/003479.htm

Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. The author and publisher are not responsible for any errors or omissions or for any consequences from application of the information herein. Medical coding is complex and subject to change; coders must consult the most current official ICD-10-CM coding guidelines and resources.

Date: December 28, 2025
Author: The Medical Coding Insights Team